Long-Term Use of Dutasteride to Treat Androgenic Alopecia in Young Men May Lead to Persistent Abnormalities in Semen Parameters

March 2025 in “ Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine ”

Y. Kim, Seung Ryeol Lee, Young Dong Yu

New to Dutasteride? There is a guide in the encyclopedia. Read the guide →

dutasteride androgenic alopecia semen parameters male fertility Avodart

Studysummary This study found that long-term use of dutasteride in men taking it for androgenetic alopecia may lead to persistent decreases in semen volume and sperm motility, potentially impacting fertility, with significant impairment observed after 17.8 to 20.3 months of treatment.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on ecerm.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia

32 citations , February 2016 in “Journal of Dermatology”

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

research Dutasteride

45 citations , January 2008 in “Drugs”

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

research A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function

October 2023 in “Journal of pharmaceutical investigation”

In this study, researchers found that among healthy Korean males, the clearance of finasteride was about 34% lower in individuals with the CYP3A5*3 homozygous allele compared to other genotypes, suggesting dosage adjustments may be necessary considering CYP3A5 and ALT levels to avoid adverse effects.

Overactive Bladder in Men: Finasteride for Androgenetic Alopecia

research Overactive bladder in men

1 citations , January 2009 in “CRC Press eBooks”

This chapter discusses the increasing prevalence of overactive bladder in aging men, examining potential causes and treatment options, without reporting new clinical results.

Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study

research Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study

36 citations , September 2018 in “American Journal of Clinical Dermatology”

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.